Chantal Michel1, Stephan Ruhrmann2, Benno G Schimmelmann3, Joachim Klosterkötter2, Frauke Schultze-Lutter3. 1. Research Department, University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bolligenstrasse 111, Haus A, 3000, Bern 60, Switzerland. chantal.michel@kjp.unibe.ch. 2. Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany. 3. Research Department, University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bolligenstrasse 111, Haus A, 3000, Bern 60, Switzerland.
Abstract
BACKGROUND: The main focus of research on clinical high-risk states for psychosis (CHR) has been the development of algorithms to predict psychosis. Consequently, other outcomes have been neglected, and little is known about the long-term diagnostic and functional outcome among those not converting to psychosis. METHODS: In a naturalistic study, incidence, persistence, and remission rates of CHR states according to symptomatic ultra-high risk or cognitive disturbances criteria were investigated in 160 of 246 outpatients of an early detection of psychoses service (21.1% CHR negative and 78.9% CHR positive at baseline) who had not converted to psychosis within follow-up (median 53.7 months, range 13.9-123.7 months). RESULTS: Remission rate of CHR status was 43.3% of all 194 CHR-positive cases, including converters, or 72.4% if only the 116 non-converters were considered, persistence rate was 27.6%, and new occurrence rate in initially CHR-negative patients was 9.1%. At follow-up, 54.5% of the non-converters met criteria of at least one Axis-I diagnosis, mainly affective and anxiety disorders, and had functional problems. The severity of risk at baseline was not associated with a higher presence of Axis-I diagnosis at follow-up. CONCLUSIONS: During follow-up, CHR symptoms remitted in one-third of initially CHR-positive patients, while almost 10% met CHR criteria newly in CHR-negative adults presenting at early detection services. The presence of CHR criteria seems to maintain the risk for lower functioning and mental disorders, particularly for affective disorders. Thus, therapeutic efforts targeting CHR patients should also focus on the current mental disorders as well as social and role functions to improve the long-term outcome.
BACKGROUND: The main focus of research on clinical high-risk states for psychosis (CHR) has been the development of algorithms to predict psychosis. Consequently, other outcomes have been neglected, and little is known about the long-term diagnostic and functional outcome among those not converting to psychosis. METHODS: In a naturalistic study, incidence, persistence, and remission rates of CHR states according to symptomatic ultra-high risk or cognitive disturbances criteria were investigated in 160 of 246 outpatients of an early detection of psychoses service (21.1% CHR negative and 78.9% CHR positive at baseline) who had not converted to psychosis within follow-up (median 53.7 months, range 13.9-123.7 months). RESULTS: Remission rate of CHR status was 43.3% of all 194 CHR-positive cases, including converters, or 72.4% if only the 116 non-converters were considered, persistence rate was 27.6%, and new occurrence rate in initially CHR-negative patients was 9.1%. At follow-up, 54.5% of the non-converters met criteria of at least one Axis-I diagnosis, mainly affective and anxiety disorders, and had functional problems. The severity of risk at baseline was not associated with a higher presence of Axis-I diagnosis at follow-up. CONCLUSIONS: During follow-up, CHR symptoms remitted in one-third of initially CHR-positive patients, while almost 10% met CHR criteria newly in CHR-negative adults presenting at early detection services. The presence of CHR criteria seems to maintain the risk for lower functioning and mental disorders, particularly for affective disorders. Thus, therapeutic efforts targeting CHR patients should also focus on the current mental disorders as well as social and role functions to improve the long-term outcome.
Entities:
Keywords:
Axis-I diagnosis; Clinical high risk; Non-conversion; Persistence; Remission
Authors: Danielle A Schlosser; Sarah Jacobson; Qiaolin Chen; Catherine A Sugar; Tara A Niendam; Gang Li; Carrie E Bearden; Tyrone D Cannon Journal: Schizophr Bull Date: 2011-08-08 Impact factor: 9.306
Authors: Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: F Schultze-Lutter; C Michel; S J Schmidt; B G Schimmelmann; N P Maric; R K R Salokangas; A Riecher-Rössler; M van der Gaag; M Nordentoft; A Raballo; A Meneghelli; M Marshall; A Morrison; S Ruhrmann; J Klosterkötter Journal: Eur Psychiatry Date: 2015-02-27 Impact factor: 5.361
Authors: Raimo K R Salokangas; Stephan Ruhrmann; Heinrich Graf von Reventlow; Markus Heinimaa; Tanja Svirskis; Tiina From; Sinikka Luutonen; Georg Juckel; Don Linszen; Peter Dingemans; Max Birchwood; Paul Patterson; Frauke Schultze-Lutter; Joachim Klosterkötter Journal: Schizophr Res Date: 2012-03-31 Impact factor: 4.939
Authors: Frauke Schultze-Lutter; Stephan Ruhrmann; Paolo Fusar-Poli; Andreas Bechdolf; Benno G Schimmelmann; Joachim Klosterkötter Journal: Curr Pharm Des Date: 2012 Impact factor: 3.116
Authors: Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Colleen A McFarlane; Mats Hallgren; Patrick D McGorry Journal: Schizophr Res Date: 2003-03-01 Impact factor: 4.939
Authors: Nikolaos Koutsouleris; Lana Kambeitz-Ilankovic; Stephan Ruhrmann; Marlene Rosen; Anne Ruef; Dominic B Dwyer; Marco Paolini; Katharine Chisholm; Joseph Kambeitz; Theresa Haidl; André Schmidt; John Gillam; Frauke Schultze-Lutter; Peter Falkai; Maximilian Reiser; Anita Riecher-Rössler; Rachel Upthegrove; Jarmo Hietala; Raimo K R Salokangas; Christos Pantelis; Eva Meisenzahl; Stephen J Wood; Dirk Beque; Paolo Brambilla; Stefan Borgwardt Journal: JAMA Psychiatry Date: 2018-11-01 Impact factor: 21.596
Authors: Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306
Authors: Zachary B Millman; Caroline Roemer; Teresa Vargas; Jason Schiffman; Vijay A Mittal; James M Gold Journal: Schizophr Bull Date: 2022-09-01 Impact factor: 7.348
Authors: Gemma Modinos; Anja Richter; Alice Egerton; Ilaria Bonoldi; Matilda Azis; Mathilde Antoniades; Matthijs Bossong; Nicolas Crossley; Jesus Perez; James M Stone; Mattia Veronese; Fernando Zelaya; Anthony A Grace; Oliver D Howes; Paul Allen; Philip McGuire Journal: Neuropsychopharmacology Date: 2021-05-03 Impact factor: 7.853